Easterly Investment Partners’s OptiNose OPTN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-156,666
| Closed | -$1.44M | – | 204 |
|
|
2025
Q1 | $1.44M | Buy |
156,666
+109,999
| +236% | +$690K | 0.12% | 124 |
|
|
2024
Q4 | $312K | Sell |
46,667
-110,616
| -70% | -$974K | 0.02% | 185 |
|
|
2024
Q3 | $1.58M | Buy |
157,283
+7,535
| +5% | +$110K | 0.13% | 137 |
|
|
2024
Q2 | $2.34M | Buy |
149,748
+13,879
| +10% | +$232K | 0.21% | 101 |
|
|
2024
Q1 | $2.98M | Buy |
135,869
+34,448
| +34% | +$765K | 0.23% | 100 |
|
|
2023
Q4 | $1.96M | Buy |
101,421
+17,605
| +21% | +$321K | 0.21% | 105 |
|
|
2023
Q3 | $1.55M | Buy |
83,816
+20,675
| +33% | +$372K | 0.17% | 112 |
|
|
2023
Q2 | $1.16M | Buy |
63,141
+13,953
| +28% | +$330K | 0.1% | 139 |
|
|
2023
Q1 | $1.42M | Hold |
49,188
| – | – | 0.13% | 127 |
|
|
2022
Q4 | $1.36M | Buy |
49,188
+35
| +0.1% | +$1.33K | 0.12% | 127 |
|
|
2022
Q3 | $2.7M | Buy |
49,153
+5,000
| +11% | +$274K | 0.26% | 88 |
|
|
2022
Q2 | $2.42M | Buy |
44,153
+8,853
| +25% | +$326K | 0.22% | 97 |
|
|
2022
Q1 | $1.31M | Buy |
35,300
+2,348
| +7% | +$83.8K | 0.1% | 128 |
|
|
2021
Q4 | $801K | Buy |
32,952
+10,060
| +44% | +$337K | 0.06% | 145 |
|
|
2021
Q3 | $1.03M | Buy |
+22,892
| New | +$960K | 0.07% | 139 |
|
Easterly Investment Partners's OPTN Position: Q2 2025 in Review
Easterly Investment Partners sold out of OptiNose (OPTN) in Q2 2025, closing a stake of 156,666 shares — an estimated $1.44M sold.
Easterly Investment Partners first reported a position in OPTN in Q3 2021 and held it in 15 quarters. The position peaked at $2.98M in Q1 2024. 0 funds tracked by Wall St. Rank hold OPTN as of Q2 2025.
- Easterly Investment Partners reported no remaining OptiNose position as of Q2 2025 after selling out during the quarter.
- Easterly Investment Partners sold 156,666 OptiNose shares in Q2 2025, an estimated $1.44M.
- Easterly Investment Partners first reported a position in OptiNose in Q3 2021 and held it in 15 quarters.
- Easterly Investment Partners's OptiNose position peaked at $2.98M in Q1 2024.
- 0 funds tracked by Wall St. Rank held OptiNose as of Q2 2025.
Based on Easterly Investment Partners's 13F filing for Q2 2025, filed 29 Jul 2025.